NOVARTIS

Biopharma

DC, USLatest filing Mar 9, 2026In-house team

$10.3M

Reported spend

Budget/Appropriations leads by disclosed activity

Filings

Most recent on Mar 9, 2026

Firms engaged

NOVARTIS leads by reported spend

AI Industry Profile

Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.

ApprovedSource: ai

Confidence

95%

Dominant share

100%

Industry count

Biopharma

100%

Client is explicitly NOVARTIS with filings focused on drug pricing, FDA, Medicare/Medicaid, 340B, patent/IP, and biopharmaceutical innovation — consistent with a major pharmaceutical/biotech company.

Reported Spend Over Time

Annual totals based on disclosed filing amounts.

2025

$6.7M3 filings

2026

$3.6M3 filings

What They're Lobbying On

Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.

Budget/Appropriations

BUD

6 mentions6 filingsLatest Mar 9, 2026

$1.5M

apportioned spend

Executive Office of the President (EOP)6HOUSE OF REPRESENTATIVES6SENATE6White House Office

Top Firms

The lobbying registrants handling this client, ranked by disclosed filing amounts.

NOVARTIS

Biopharma

6 filingsLatest Mar 9, 2026

Federal Government Relations/Legislative Affairs

$10.3M

Top Lobbyists

Lobbyists are ranked by appearances and an equal share of each filing's reported amount.

Recent Filings

The latest disclosures for this client.

NOVARTIS

2025 third quarter7 issues8 lobbyists

Budget/AppropriationsHealth IssuesMedicare/Medicaid

$1.7M

Mar 9, 2026

NOVARTIS

AI Industry Profile

Reported Spend Over Time

What They're Lobbying On

Budget/Appropriations

Top Firms

Top Lobbyists

Recent Filings

Government Touchpoints

Attributed Recipients

Copyright/Patent/Trademark

Health Issues

Labor Issues/Antitrust/Workplace

Medicare/Medicaid

Taxation/Internal Revenue Code

Trade (domestic/foreign)